Effect of Cinacalcet Combined with Calcitriol and Sevelamer on Intact Parathyroid Hormone Levels in Hemodialysis Patients with Tertiary Hyperparathyroidism

RONG Jing; ZHOU Hong; ZHANG Hui; LI Jing; YANG Jianping

PDF(2441 KB)

Journal of Hunan Normal University(Medical Science) ›› 2025, Vol. 22 ›› Issue (5) : 173-177.

Effect of Cinacalcet Combined with Calcitriol and Sevelamer on Intact Parathyroid Hormone Levels in Hemodialysis Patients with Tertiary Hyperparathyroidism

RONG Jing, ZHOU Hong, ZHANG Hui, LI Jing, YANG Jianping

Author information +

History +

Abstract

Objective To evaluate the efficacy of cinacalcet combined with calcitriol and sevelamer (triple therapy) in hemodialysis patients with tertiary hyperparathyroidism (THPT). Methods This retrospective study included 120 THPT patients treated at Xinjiang 474 Hospital (January 2021-July 2024). Patients were randomized into: control group (calcitriol+sevelamer, n=60) and observation group (triple therapy, n=60). Outcomes included intact parathyroid hormone (iPTH), cardiac function, vascular calcification, and quality of life. Results Compared with controls, the serum iPTH level, vascular calcification score and total adverse reaction rate were lower in the observation group after treatment. Cardiovascular parameters improved better; the quality of life score and total effective rate were higher. Conclusion Triple therapy effectively reduces iPTH, slows vascular calcification progression with favorable safety in hemodialysis patients with THPT.

Key words

cinacalcet / tertiary hyperparathyroidism / hemodialysis / intact parathyroid hormone

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

RONG Jing, ZHOU Hong, ZHANG Hui, LI Jing, YANG Jianping. Effect of Cinacalcet Combined with Calcitriol and Sevelamer on Intact Parathyroid Hormone Levels in Hemodialysis Patients with Tertiary Hyperparathyroidism[J]. Journal of Hunan Normal University(Medical Science). 2025, 22(5): 173-177

References

[1] 相华, 常帅, 郑海燕, 等. 西那卡塞治疗肾移植术后三发性甲状旁腺功能亢进的临床疗效及安全性研究[J]. 实用药物与临床. 2024, 27(12): 894-898.
[2] 李洛华, 蒋红樱. 基于NHANES调查分析慢性肾脏病患者血清25(OH) D与全因死亡和心血管疾病死亡的相关性[J]. 现代预防医学, 2024, 51(9): 1555-1561.
[3] LIU X, LIU Y, ZHENG P, et al.Effects of active vitamin D analogs and calcimimetic agents on PTH and bone mineral biomarkers in hemodialysis patients with SHPT: a network meta-analysis[J]. Eur J Clin Pharmacol, 2024, 80(10): 1555-1569.
[4] SONG Z, WU C, WANG R, et al.The Effects of Parathyroidectomy vs Medical Treatments for Secondary Hyperparathyroidism in Patients Undergoing Dialysis: A Meta-Analysis[J]. Endocr Pract, 2024, 30(6): 569-576.
[5] GOTO S, HAMANO T, FUJII H, et al.Hypocalcemia and cardiovascular mortality in cinacalcet users[J]. Nephrol Dial Transplant, 2024, 39(4): 637-647.
[6] GARG Y, VAISHNAV M S, GARG N, et al.Parathyroid Carcinoma Complicated by Parathyromatosis and Refractory Hypercalcemia[J]. Cureus, 2024, 16(10): e72584.
[7] 袁芊芊, 吴高松, 田文.2022年《美国内分泌外科医师学会继发性和三发性甲状旁腺功能亢进症外科治疗指南》解读[J]. 中国实用外科杂志, 2022, 42(12): 1367-1371.
[8] SENANAYAKE S, GUNAWARDENA N, PALIHAWADANA P, et al.Validity and reliability of the Sri Lankan version of the kidney disease quality of life questionnaire (KDQOL-SF)[J]. Health Qual Life Outcomes, 2017, 15(1): 119.
[9] CHOUDHURY A, JOHN A R, SHARMA M, et al.Refractory Secondary Hyperparathyroidism in Chronic Renal Impairment: Is Surgery a Viable Option to Achieve a Biochemical Balance in Patients Failing Medical Management?[J]. Indian J Otolaryngol Head Neck Surg, 2025, 77(2): 754-759.
[10] 吕桂兰, 曹虎男, 王浩, 等. 维持性血液透析中低血压风险预测的Meta建模及验证[J]. 中华护理杂志, 2024, 59(21): 2611-2619.
[11] YAMADA S, TOKUMOTO M, TANIGUCHI M, et al.Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism[J]. Ther Apher Dial, 2015, 19(4): 367-377.
[12] LIU D, QIN H, YANG J, et al.Different effects of Wnt/beta-catenin activation and PTH activation in adult and aged male mice metaphyseal fracture healing[J]. BMC Musculoskelet Disord, 2020, 21(1): 110.
[13] SATO H, SAKAKURA K, JINNOUCHI H, et al.The Impact of the Coronary Artery Calcium Score on the Clinical Outcomes in Patients with Acute Myocardial Infarction[J]. J Clin Med, 2024, 13(23): 7136.
[14] DARYADEL A, KUNG C J, HAYKIR B, et al.The calcium-sensing receptor has only a parathyroid hormone-dependent role in the acute response of renal phosphate transporters to phosphate intake[J]. Am J Physiol Renal Physiol, 2024, 326(5): F792-F801.
[15] KOMABA H, NAKANISHI S, FUJIMORI A, et al.Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism[J]. Clin J Am Soc Nephrol, 2010, 5(12): 2305-2314.
[16] 王强, 牛津津, 周亚非, 等. 沙库巴曲缬沙坦钠片联合维立西呱治疗慢性心力衰竭的效果及对患者心功能、心脏结构重塑、血管内皮功能的影响[J]. 海南医学, 2024, 35(14): 1991-1996.
[17] PALMER S C, MAVRIDIS D, JOHNSON D W, et al.Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis[J]. Am J Kidney Dis, 2020, 76(3): 321-330.
[18] HENLEY C, DAVIS J, MILLER G, et al.The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats[J]. Eur J Pharmacol, 2009, 616(1-3): 306-313.
[19] GOODMAN W G, WARD D T, MARTIN K J, et al.Activation of the Calcium Receptor by Calcimimetic Agents Is Preserved Despite Modest Attenuating Effects of Hyperphosphatemia[J]. J Am Soc Nephrol, 2022, 33(1): 201-212.